Evidence map›Paper›PMID 33990184›Full record

ArticleBMC gastroenterology2021

Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis.

Yaw-Sen Chen, Pei-Min Hsieh, Hung-Yu Lin, Chao-Ming Hung, Gin-Ho Lo, Yao-Chun Hsu, I-Cheng Lu, Chih-Yuan Lee, Tsung-Chin Wu, Jen-Hao Yeh and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Surgical Outcomes for Hepatocellular Carcinoma in Patients with Child-Pugh Class B: a Retrospective Multicenter Study.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yaw-Sen Chen *School of Medicine, College of Medicine, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Pei-Min Hsieh *Department of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Hung-Yu Lin *School of Medicine, College of Medicine, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Chao-Ming HungSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Gin-Ho LoDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Yao-Chun HsuDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
I-Cheng LuHealth Examination Center, E-Da Hospital, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Chih-Yuan LeeDepartment of Surgery, National Taiwan University Hospital, Taipei, 100, Taiwan, ROC.
Tsung-Chin WuDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 807, Taiwan, ROC.
Jen-Hao YehDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 807, Taiwan, ROC.
Pojen HsiaoDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 807, Taiwan, ROC.
Yu-Chan LiSchool of Medicine, College of Medicine, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Ya-Chin WangDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 807, Taiwan, ROC.
Kun-Chou HsiehDepartment of Surgery, E-Da Hospital, I-Shou University, Kaohsiung, 824, Taiwan, ROC.
Chih-Wen LinDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 807, Taiwan, ROC. lincw66@gmail.com.ORCID http://orcid.org/0000-0003-2344-5056
E-Da Hospital · TWI-Shou University · TWChina Medical University · TWNational Taiwan University Hospital · TW

Funding

E-Da Hospital EDAHP109044E-Da Hospital EDAHP109045E-Da Hospital EDAHP109053E-Da Hospital EDPJ105056E-Da Hospital EDPJ106094E-Da Hospital EDPJ107076E-Da Hospital EDPJ108069E-Da Hospital EDPJ109072E-Da Hospital-National Taiwan University Hospital Joint Research Program 105-EDN13E-Da Hospital-National Taiwan University Hospital Joint Research Program 108-EDN11E-Da Hospital-National Taiwan University Hospital Joint Research Program 109-EDN03Ministry of Science and Technology, Taiwan 108-2314-B-214-006-MY2
6 · The paper itself

Abstract

backgroundThe benefits of surgical resection (SR) for various Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma (HCC) remain unclear. We investigated the risk factors of overall survival (OS) and survival benefits of SR over nonsurgical treatments in patients with HCC of various BCLC stages.

methodsOverall, 2316 HCC patients were included, and their clinicopathological data and OS were recorded. OS was analyzed by the Kaplan-Meier method and Cox regression analysis. Propensity score matching (PSM) analysis was performed.

resultsIn total, 66 (2.8%), 865 (37.4%), 575 (24.8%) and 870 (35.0%) patients had BCLC stage 0, A, B, and C disease, respectively. Furthermore, 1302 (56.2%) of all patients, and 37 (56.9%), 472 (54.6%), 313 (54.4%) and 480 (59.3%) of patients with BCLC stage 0, A, B, and C disease, respectively, died. The median follow-up duration time was 20 (range 0-96) months for the total cohort and was subdivided into 52 (8-96), 32 (1-96), 19 (0-84), and 12 (0-79) months for BCLC stages 0, A, B, and C cohorts, respectively. The risk factors for OS were (1) SR and cirrhosis; (2) SR, cirrhosis, and Child-Pugh (C-P) class; (3) SR, hepatitis B virus (HBV) infection, and C-P class; and (4) SR, HBV infection, and C-P class for the BCLC stage 0, A, B, and C cohorts, respectively. Compared to non-SR treatment, SR resulted in significantly higher survival rates in all cohorts. The 5-year OS rates for SR vs. non-SR were 44.0% versus 28.7%, 72.2% versus 42.6%, 42.6% versus 36.2, 44.6% versus 23.5%, and 41.4% versus 15.3% (all P values < 0.05) in the total and BCLC stage 0, A, B, and C cohorts, respectively. After PSM, SR resulted in significantly higher survival rates compared to non-SR treatment in various BCLC stages.

conclusionsSR conferred significant survival benefits to patients with HCC of various BCLC stages and should be considered a recommended treatment for select HCC patients, especially patients with BCLC stage B and C disease.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHepatectomyHumansNeoplasm StagingPropensity ScoreRetrospective StudiesTreatment OutcomeHepatitis B virusHepatocellular carcinomaOverall survivalPrognosisSurgical resection

Identifiers

PMID33990184
PMCPMC8120780
OpenAlexW3123906687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.